AstraZeneca to Shut R&D Sites

March 2, 2010
Sites will be closed in Britain, Sweden and activities reduced in Delaware facility

Pharmaceutical giant AstraZeneca on March 2 said it would shut research and development sites in Britain and Sweden and reduce U.S. operations as part of previously announced plans to axe 8,000 jobs.

The company had said in January said that it was looking to cut 8,000 jobs worldwide by 2014, including 3,500 R&D positions.

On March 2 it said it would close an R&D center in Leicestershire, central England, and a smaller site in Cambridge, close to London.

It added that it would shut a research site in Lund, Sweden, and reduce activities at a facility in Wilmington, Delaware.

"AstraZeneca today shared with its employees further details of proposals designed to improve the productivity of its global research and development organization," the group said.

"The proposed changes, first outlined at the end of January, include focusing research efforts on a smaller number of disease areas and consolidating activities onto a reduced global footprint through the merger of some sites. Some of our sites will close," it added.

Copyright Agence France-Presse, 2010

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!